Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?

炎症 类风湿性关节炎 医学 疾病 冠状动脉疾病 免疫系统 细胞因子 药理学 临床试验 受体 药物开发 免疫学 药品 内科学
作者
Elijah Genetzakis,Jayson Gilchrist,Michael Kassiou,Gemma A. Figtree
出处
期刊:Pharmacology & Therapeutics [Elsevier]
卷期号:237: 108228-108228 被引量:9
标识
DOI:10.1016/j.pharmthera.2022.108228
摘要

The purinoceptor 7 receptor (P2X7R) plays an important role in promoting inflammation in response to accumulating damage-associated molecular patterns (DAMPs) released from stressed or apoptotic cells and has been connected to various pathological conditions. The initial investment by large pharmaceutical companies such as AstraZeneca and Pfizer led to the development of several classes of P2X7R antagonists for the treatment of rheumatoid arthritis and Crohn’s disease. While these compounds showed early promise as therapeutic agents and were found to potently inhibit adenosine triphosphate (ATP)-induced release of interleukin 1 beta (IL-1β) in patient-derived monocytes primed with lipopolysaccharide (LPS), they failed to elicit a therapeutic benefit in phase II clinical trials. Within the last 10 years, a wealth of strong preclinical and clinical evidence has implicated IL-1β as an aggressor in the development and progression of cardiovascular diseases, a cytokine modulated by the P2X7R. On account of the immune-mediated events that regulate atherosclerosis, antagonism of the P2X7R has been proposed as a therapeutic strategy due to the unique functionality of the receptor as an instigator of sterile inflammation. Here, we review the success and failures in P2X7R drug development to evaluate the major barriers to successful clinical translation of P2X7R antagonists. These avenues should be addressed by researchers and pharmaceutical companies to ensure future clinical success in the treatment of CAD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
舒心的怡发布了新的文献求助10
5秒前
xiaodu20230228完成签到 ,获得积分10
6秒前
7秒前
8秒前
9秒前
12秒前
WSND发布了新的文献求助10
13秒前
13秒前
14秒前
zmx完成签到 ,获得积分10
15秒前
孔刚完成签到 ,获得积分10
18秒前
华仔应助yuanr采纳,获得10
18秒前
只谈风月发布了新的文献求助10
19秒前
20秒前
舒心的怡完成签到,获得积分10
20秒前
lybcrystal完成签到,获得积分10
24秒前
WSND发布了新的文献求助10
24秒前
25秒前
25秒前
25秒前
26秒前
我是老大应助不安溪灵采纳,获得10
28秒前
30秒前
lalalapa666发布了新的文献求助10
30秒前
peiling发布了新的文献求助10
32秒前
研友_57A745完成签到,获得积分10
33秒前
Okpooko完成签到,获得积分20
33秒前
34秒前
WSND发布了新的文献求助10
34秒前
英俊的铭应助陈倩雯采纳,获得10
35秒前
科研通AI2S应助清脆香露采纳,获得10
36秒前
Ava应助z1z1z采纳,获得10
36秒前
DY应助清脆香露采纳,获得10
36秒前
38秒前
热情的十八完成签到,获得积分10
41秒前
香蕉觅云应助科研通管家采纳,获得10
42秒前
orangebee应助科研通管家采纳,获得10
42秒前
田様应助科研通管家采纳,获得10
42秒前
42秒前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
IG Farbenindustrie AG and Imperial Chemical Industries Limited strategies for growth and survival 1925-1953 800
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 600
Prochinois Et Maoïsmes En France (et Dans Les Espaces Francophones) 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
Offline version of the Proceedings of 15th EWTEC 2023, Bilbao 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2534165
求助须知:如何正确求助?哪些是违规求助? 2171315
关于积分的说明 5579655
捐赠科研通 1891539
什么是DOI,文献DOI怎么找? 942653
版权声明 565075
科研通“疑难数据库(出版商)”最低求助积分说明 502437